Yahoo
NYSE American - Delayed Quote USD

NeurAxis, Inc. (NRXS)

7.49 -0.06 (-0.79%)
As of 9:30:00 AM EDT. Market Open.
Chart Range Bar
Loading chart for NRXS
  • Previous Close 7.55
  • Open 7.49
  • Bid 7.37 x 20000
  • Ask 7.56 x 10000
  • Day's Range 7.49 - 7.49
  • 52 Week Range 2.21 - 9.33
  • Volume 261
  • Avg. Volume 127,476
  • Market Cap (intraday) 94.058M
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) --
  • EPS (TTM) -0.78
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 11.00
  • Zacks Rating Neutral

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

neuraxis.com

24

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NRXS
64.98%
S&P 500 (^GSPC)
11.40%

1-Year Return

NRXS
168.46%
S&P 500 (^GSPC)
11.78%

3-Year Return

NRXS
251.64%
S&P 500 (^GSPC)
83.01%

5-Year Return

NRXS
18.89%
S&P 500 (^GSPC)
65.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.93M
Earnings -2.28M
Profit Margin -118.07%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

-2M
-1M
0
1M
-250.0%
-200.0%
-150.0%

Analyst Insights

View More

Analyst Price Targets

9.00
11.00 Average
7.49 Current
13.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/20/2026
Analyst Craig-Hallum
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 8 -> 13

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -144.44%

  • Return on Assets (ttm)

    -56.21%

  • Return on Equity (ttm)

    -139.76%

  • Revenue (ttm)

    5.32M

  • Net Income Avi to Common (ttm)

    -8.45M

  • Diluted EPS (ttm)

    -0.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.32M

  • Total Debt/Equity (mrq)

    4.15%

  • Levered Free Cash Flow (ttm)

    -3.15M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: